Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells
- 11 March 2008
- journal article
- review article
- Published by Elsevier
- Vol. 127 (3) , 280-285
- https://doi.org/10.1016/j.clim.2008.01.011
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous systemAnnals of the Rheumatic Diseases, 2007
- Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide‐resistant proliferative lupus nephritisArthritis & Rheumatism, 2007
- Progressive multifocal leukoencephalopathy in systemic lupus erythematosusArthritis & Rheumatism, 2007
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006
- Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivoJournal of Clinical Investigation, 2006
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- B Lymphocyte Selection and Survival in Systemic LupusInternational Archives of Allergy and Immunology, 2004
- Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3 The Journal of Experimental Medicine, 2003
- Immunoglobulin synthesis and generalized autoimmunity in mice congenitally deficient in αβ(+) T cellsNature, 1994
- Involvement of JC Virus–Infected Mononuclear Cells from the Bone Marrow and Spleen in the Pathogenesis of Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 1988